Search
forLearn
5 / 801 resultslearn Isodon Amethystoides
learn gentian
learn Tri-Salts
learn trimethicone
Research
5 / 254 resultsresearch Symmetrical drug‐related intertriginous and flexural exanthema like eruption associated with COVID‐19 vaccination
A skin rash after the AstraZeneca COVID-19 vaccine was treated successfully with medication.
research Dermatological problems in the football player
Football players can get many skin conditions from their sport, which need different treatments and can be prevented with good hygiene and protection.
research 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
research Drug Eruptions
Any medication can cause skin reactions, some due to allergies and others due to dosage or genetic factors.
research Cutaneous Side Effects of Chemotherapy and Radiotherapy
Chemotherapy and radiotherapy can cause skin side effects like rashes, hair loss, and nail changes, which are usually managed with conservative treatments.
Community Join
5 / 1000+ resultscommunity Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
community My experience with Trichogenics
A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community Kintor starts a new Phase 3 for Pyri... (1+ year)
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.